<DOC>
	<DOCNO>NCT00858793</DOCNO>
	<brief_summary>Patient stem cell mobilize induction chemotherapy ( R ) -ICE G-CSF . If sufficient cell mobilize , patient treat high-dose chemotherapy transplant autologous CD34+ cell transduce antiviral vector ( M87o ) . If autologous CD34+ yield insufficient , allogeneic gene-modified cell give , compatible donor available . To minimize risk transplant failure , second unmodified CD34+ cell transplant give one week first transplant .</brief_summary>
	<brief_title>High-dose Chemotherapy With Transplantation Gene-modified Haematopoietic Stem Cells HIV-positive Patients With Malignant Diseases Indicating HSCT</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , AIDS-Related</mesh_term>
	<criteria>Male female patient ethnic group age 18 65 year HIVpositive patient malignant disease blood ( NHL , Hodgkin disease , plasmocytoma , acute chronic leukaemia ) fail achieve complete remission ( CR ) standarddose firstline chemotherapy chemosensitive relapse initial CR Patients must receive HAART Any follow condition : congestive heart failure ( NYHA &gt; II ) document EBV , HBV HCV infection ( allogeneic PBSCT ) creatinine clearance &lt; 60 ml/min leave ventricular ejection fraction &lt; 40 % bilirubin &gt; 2 mg/dl Severe opportunistic infection More 10 % bone marrow involve lymphoma Between 2 5 10^6 autologous CD34+ cells/kg BW obtain leukapheresis CD34 enrichment Women child.bearing potential adequate contraceptive protection Women pregnant breast feed Known history drug , medication alcohol abuse within last 12 month precede study Participation another study investigational product within less one month prior study Simultaneous participation study investigational drug Presence disease likely require procedure alter schedule protocol Patients history seizure , central nervous system disorder psychiatric disability think clinically significant opinion investigator Patients limited mental capacity extent he/she provide inform consent information regard adverse event study medication Patients clinically meaningful renal , hepatic , respiratory cardiovascular disease Patients previously admit study Patients accept transfusion blood product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>AIDS</keyword>
	<keyword>HIV</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>gene-modified Stem Cells</keyword>
	<keyword>treatment experience</keyword>
</DOC>